Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Other Operating Expenses (2019 - 2020)

GT Biopharma (GTBP) has disclosed Other Operating Expenses for 4 consecutive years, with -$13.9 million as the latest value for Q3 2020.

  • On a quarterly basis, Other Operating Expenses rose 32.2% to -$13.9 million in Q3 2020 year-over-year; TTM through Jun 2021 was -$13.9 million, a 167.7% decrease, with the full-year FY2025 number at -$5.6 million, up 43.09% from a year prior.
  • Other Operating Expenses was -$13.9 million for Q3 2020 at GT Biopharma, down from $41.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $41.0 million in Q4 2019 to a low of -$20.5 million in Q3 2019.